Core Insights - Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs [3] Group 1: Company Overview - Belite Bio is advancing treatments for conditions such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD) [3] - The company's lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye and is currently undergoing multiple clinical trials, including a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for STGD1, as well as a Phase 3 study (PHOENIX) for GA [3] Group 2: Upcoming Events - Belite Bio will host a webcast on May 14, 2025, at 4:30 p.m. Eastern Time to discuss its financial results and provide a business update for the first quarter ended March 31, 2025 [1][2] - The webcast can be accessed via a provided link and will be available for replay for approximately 90 days after the event [2]